Black Diamond's Unique Approach
Targeting Allosteric RTK Mutants
Black Diamond Therapeutics has developed a proprietary method to uncover and target allosteric mutant oncogenes.
Black Diamond Therapeutics is using its MAP platform to extend its approach to developing drugs to a range of high value oncogenic targets.
A new class of genetically-defined driver mutations
→ Pharmacology uncovered by Black Diamond
→ Resistant to conventional, standard-of-care kinase inhibitors
→ Significant patient populations with high unmet need
Black Diamond’s MAP drug discovery platform mines and validates genetically-defined allosteric mutant oncogenes